TY - JOUR
T1 - Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy
AU - Cardinale, Daniela
AU - Sandri, Maria T.
AU - Colombo, Alessandro
AU - Colombo, Nicola
AU - Boeri, Marina
AU - Lamantia, Giuseppina
AU - Civelli, Maurizio
AU - Peccatori, Fedro
AU - Martinelli, Giovanni
AU - Fiorentini, Cesare
AU - Cipolla, Carlo M.
PY - 2005/1
Y1 - 2005/1
N2 - Background-In patients with aggressive malignancies who are undergoing high-dose chemotherapy, even minimal elevation of troponin I (TnI) is associated with late left ventricular dysfunction. The time course of the subclinical myocardial damage and its impact on the clinical outcome have never been investigated previously. Methods and Results-In 703 cancer patients, we measured TnI soon after chemotherapy (early TnI) and 1 month later (late TnI). Troponin was considered positive for values ≥0.08 ng/mL. Clinical and left ventricular ejection fraction evaluation (echocardiography) were performed before chemotherapy, 1, 3, 6, and 12 months after the end of the treatment, and again every 6 months afterward. Three different TnI patterns were identified, and patients were grouped accordingly. In 495 patients, both early and late TnI values were -/- group); in 145, there was only an early increase (TnI+/- group); and in 63 patients, both values increased (TnI+/+ group). In the TnI-/- group, no significant reduction in ejection fraction was observed during the follow-up, and there was a very low incidence of cardiac events (1%). In contrast, a greater incidence of cardiac events occurred in TnI-positive patients, particularly in the TnI+/+ group (84% versus 37% in the TnI +/- group; P
AB - Background-In patients with aggressive malignancies who are undergoing high-dose chemotherapy, even minimal elevation of troponin I (TnI) is associated with late left ventricular dysfunction. The time course of the subclinical myocardial damage and its impact on the clinical outcome have never been investigated previously. Methods and Results-In 703 cancer patients, we measured TnI soon after chemotherapy (early TnI) and 1 month later (late TnI). Troponin was considered positive for values ≥0.08 ng/mL. Clinical and left ventricular ejection fraction evaluation (echocardiography) were performed before chemotherapy, 1, 3, 6, and 12 months after the end of the treatment, and again every 6 months afterward. Three different TnI patterns were identified, and patients were grouped accordingly. In 495 patients, both early and late TnI values were -/- group); in 145, there was only an early increase (TnI+/- group); and in 63 patients, both values increased (TnI+/+ group). In the TnI-/- group, no significant reduction in ejection fraction was observed during the follow-up, and there was a very low incidence of cardiac events (1%). In contrast, a greater incidence of cardiac events occurred in TnI-positive patients, particularly in the TnI+/+ group (84% versus 37% in the TnI +/- group; P
KW - Cardiac toxicity
KW - Chemotherapy
KW - Troponin
KW - Ventricles
UR - http://www.scopus.com/inward/record.url?scp=33747791740&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33747791740&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:33747791740
VL - 1
SP - 38
EP - 43
JO - Rivista Italiana della Medicina di Laboratorio
JF - Rivista Italiana della Medicina di Laboratorio
SN - 1825-859X
IS - 1
ER -